AN2 Therapeutics, Inc.ANTXNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P17
Within normal range
vs 3Y Ago
0x
Contraction
Streak
4 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | -5.16% |
| 2024 | -4.73% |
| 2023 | 15.79% |
| 2022 | 173.16% |
| 2021 | 269.01% |
| 2020 | -27.05% |
| 2019 | 0.00% |